Tirzepatide
Other Blood Glucose Lowering Drugs, Excl. Insulins
Sold as MOUNJARO · ZEPBOUND · MOUNJARO KWIKPEN
- Drug class
- Other Blood Glucose Lowering Drugs, Excl. Insulins
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 69
Overview
Tirzepatide is an active pharmaceutical ingredient in the Other Blood Glucose Lowering Drugs, Excl. Insulins group (A10BX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 44 | May 15, 2026 |
| CA Canada | Health Canada | 24 | April 24, 2026 |
| EU European Union | EMA | 1 | February 26, 2026 |
GBUnited Kingdom· MHRA
44 products
Uses
Mounjaro is indicated: 1. For the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes.
2. , hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus). 1. 1.
How to take
CACanada· Health Canada
24 products
Uses
MOUNJARO (tirzepatide injection) is indicated for once-weekly administration as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus. • As monotherapy when metformin is inappropriate due to contraindication or intolerance.
1 Dosing Considerations and 7 WARNINGS AND PRECAUTIONS). Limitations of Use MOUNJARO has not been studied in combination with short-acting, medium-acting, or dual formulation insulins. MOUNJARO is not a substitute for insulin. MOUNJARO should not be used in patients with type 1 diabetes mellitus (formerly known as insulin-dependent diabetes mellitus or IDDM).
MOUNJARO should not be used for the treatment of diabetic ketoacidosis. 1 Pediatrics Pediatrics (<18 years of age): The safety and efficacy of MOUNJARO have not been studied in pediatric patients. MOUNJARO is not indicated for use in pediatric patients.
3 Pharmacokinetics).
EUEuropean Union· EMA
1 product
Uses
Type 2 diabetes mellitus Mounjaro is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes.
1. , hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus). 1.
How to take
Sources & citations
- [1]MHRA (UK) · PLGB148950321 · revised May 15, 2026
- [2]Health Canada (DPD) · 02541092 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/005620 · revised February 26, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.